TARSTarsus Pharmaceuticals, Inc.
Price
+33%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality mixed, nothing alarming, undemanding price, growing in the filings, the market undecided.
We are a commercial stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. We launched XDEMVY® (lotilaner ophthalmic solution) 0.25%, formerly known as TP-03, for the treatment of Demodex blepharitis, in August 2023 after receiving U.S. Food and Drug Administration (“FDA”) approval in July 2023. Demodex blepharitis is caused by the infestation of Demodex mites.
In the company’s own words · 10-K filed Feb 23, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Tarsus Pharmaceuticals, Inc. (TARS) reported revenue of $174M in Q2 2026 (quarter ended Jun 30, 2026), up 69% from the same quarter a year earlier. That came with a gross margin of 93% and net loss of $19M. For the full year FY2025, revenue was $451M (+147% year on year) and net income −$66M. Its largest product in Q3 2023 (quarter ended Sep 30, 2023) was License And Collaboration at $218K, 52% of the disclosed total, just ahead of License And Collaboration Other at 48%. The next results filing is expected around Nov 3, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 10, 2026On September 4, 2026 (the “Closing Date”), Tarsus Pharmaceuticals, Inc. (the “Company”) completed its previously announced acquisition of Alkeus Pharmaceuticals, Inc., a Delaware corporation (“Alkeus”), pursuant to that certain Agreement and Plan of Merger, dated as of July 31, 2026 (the “Merger Agreement”), by and …Acquisition or disposition completed · Form 8-K
- Aug 6, 2026Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth.Earnings release · press release
- Aug 6, 2026On August 5, 2026, Tarsus Pharmaceuticals, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with a syndicate of existing and new healthcare investors (the “Investors”) for a private placement of: (i) 2,098,519 shares (the “Initial Shares”) of common stock, par …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q3 2023 · $418.0KThe company’s own SEC segment disclosure.
- License And Collaboration$218.0K52%
- License And Collaboration Other$200.0K48%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.